Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

OBJECTIVES: To evaluate the long-term efficacy and safety of canakinumab to treat patients with colchicine-resistant familial Mediterranean fever (crFMF) during Epoch 4 (weeks 41 to 113) of the CLUSTER study. METHODS: Patients received open-label canakinumab 150 or 300 mg, every 4 or 8 weeks during...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ann Rheum Dis
Hoofdauteurs: Ozen, Seza, Ben-Cherit, Eldad, Foeldvari, Ivan, Amarilyo, Gil, Ozdogan, Huri, Vanderschueren, Steven, Marzan, Katherine, Kahlenberg, J Michelle, Dekker, Elise, De Benedetti, Fabrizio, Koné-Paut, Isabelle
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2020
Onderwerpen:
Autoinflammatory Disorders
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509527/
https://ncbi.nlm.nih.gov/pubmed/32571870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-217419
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items